Denali Therapeutics Inc.
DNLIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Denali Therapeutics Inc. focuses on Biotechnology services and products. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. At a $3.53B market cap, Denali Therapeutics Inc. ranks as a mid-cap company within healthcare. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Market Cap
$3.53B
Beta
1.00
P/E (TTM)
—
P/E (Fwd)
-9.07
EPS (TTM)
$-2.84
EPS (Fwd)
$-2.43
ROE
-54.9%
ROA
-29.1%
Cash
$710.5M
Total Debt
$37.7M
Free CF
-$268.5M
52W Change
52.2%
Annual Financials
Cash vs Debt
Where DNLI stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, DNLI finished 13.75% above its 150-day moving average ($21.60) and 19.21% above its 200-day moving average ($20.61). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DNLI overbought or oversold?
At the August 27, 2026 close, DNLI's RSI(14) was 48.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Denali Therapeutics Inc. holds $710.5M in cash against $37.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$268.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -54.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $108.5M (2022) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, DNLI has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Denali Therapeutics Inc.'s trajectory.